Livzon Pharmaceutical Group Inc.

000513

CNE0000002Y8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 05/06/2024 am IST			5-day change	1st Jan Change
39.71 ^CNY	-0.25%		+2.06%	+13.42%

01:00am	Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	RE
01:00am	Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	RE

Livzon Pharmaceutical Group Inc. Provides Earning Guidance for the Year Ended December 31, 2015

January 29, 2016 at 04:10 pm IST

Livzon Pharmaceutical Group Inc. provided earning guidance for the year ended December 31, 2015. For the period, the company expects net profit attributable to the shareholders to be in range of RMB 593,375,200 to RMB 644,973,000 and basic earnings per share expected to be in range of RMB 1.54 to RMB 1.68 per share.

Latest news about Livzon Pharmaceutical Group Inc.

Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	04:30am	RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	04:30am	RE
Livzon Pharmaceutical Cancels 5.3 Million Share Options	27/05	MT
Livzon Pharmaceutical Group Cancels Share Options	14/05	MT
Livzon Pharmaceutical Declares Final Dividend for 2023	14/05	MT
Livzon Pharmaceutical Factory Receives Approval for the U.S. FDA Approval for the Company's Drug Cetrorelix Acetate for Injection	26/04	CI
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%	24/04	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04	CI
Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.	02/04	CI
Livzon Pharma's 2023 Profit Rises 2%; Revenue Falls 2%	29/03	MT
Livzon Pharmaceutical Group Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Livzon Pharmaceutical Group Inc. Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 05 August 2024	28/03	CI
Livzon Pharma to Trial JP-1366 Tablets as Reflux Esophagitis Drug	23/02	MT
Livzon Group Livzon Medical Research Centre Receives Notice of Drug Clinical Trial Approval Issued by China National Medical Products Administration	22/02	CI
Livzon Pharma Gets Nod to Trial Weight Management Drug	06/02	MT
Livzon Pharmaceutical Appoints Former Joincare Exec as Vice President	30/01	MT
Livzon Pharmaceutical Group Inc. commences an Equity Buyback Plan for CNY 600 million worth of its shares, under the authorization approved on Decemeber 19, 2023.	18/01	CI
Livzon Pharma Recognizes Credit, Asset Impairments	10/01	MT
Livzon Pharmaceutical to Continue Getting Services from Joincare Pharmaceutical	02/01	MT
Livzon Pharmaceutical Shareholders to Vote on Spin-Off, Separate Listing of Livzon Diagnostics	19/12	MT
Livzon Pharma's 190 Products Added to China's National Reimbursement Drug List	14/12	MT
Chinese Drug Regulator Includes Livzon Pharmaceutical Unit's SARS-COV-2 Vaccine for Emergency Use	04/12	MT
Livzon MABPharm Inc. Announces the Inclusion of Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (Cho Cell) for Emergency Use	03/12	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 5% stake in Zhuhai Livzon Diagnostics Inc. from Shi Jianfeng.	21/11	CI
Livzon Pharmaceutical Group Inc. completed the acquisition of an additional 3% stake in Zhuhai Livzon Diagnostics Inc. from Li Lin.	21/11	CI

Chart Livzon Pharmaceutical Group Inc.

Duration

Period

More charts

Company Profile

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

14/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Livzon Pharmaceutical Group Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

39.71 CNY

Average target price

41.14 CNY

Spread / Average Target

+3.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIVZON PHARMACEUTICAL GROUP INC.	+13.42%	444.76Cr
ELI LILLY AND COMPANY	+42.69%	75TCr
NOVO NORDISK A/S	+38.66%	61TCr
JOHNSON & JOHNSON	-6.87%	35TCr
MERCK & CO., INC.	+18.74%	33TCr
ABBVIE INC.	+6.76%	29TCr
ASTRAZENECA PLC	+18.32%	25TCr
ROCHE HOLDING AG	-2.99%	21TCr
NOVARTIS AG	+11.04%	22TCr
PFIZER, INC.	+2.64%	17TCr

Other Pharmaceuticals